Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial

Sensitivity to iron dextran is a potent obstacle to maintaining optimum iron status in patients with dialysis-associated anemia. As part of the North American clinical trials for iron sucrose injection, we examined the effect of intravenous (IV) iron sucrose in 23 hemodialysis patients with document...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2000-07, Vol.36 (1), p.88-97
Hauptverfasser:	Van Wyck, David B., Cavallo, Guilio, Spinowitz, Bruce S., Adhikarla, Rohini, Gagnon, Suzanne, Charytan, Chaim, Levin, Nathan
Format:	Artikel
Sprache:	eng
Schlagworte:	anemia Anemia, Iron-Deficiency - blood Anemia, Iron-Deficiency - drug therapy Anemia, Iron-Deficiency - etiology Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Pressure - drug effects chronic kidney failure (CRF) Drug Hypersensitivity - etiology Emergency and intensive care: renal failure. Dialysis management Epoetin Alfa Erythropoietin - therapeutic use Ferric Compounds - administration & dosage ferritin General and cellular metabolism. Vitamins Glucaric Acid Hematinics - therapeutic use Humans Infusions, Intravenous Injections, Intravenous Intensive care medicine Iron iron deficiency iron dextran iron sucrose Iron-Dextran Complex - adverse effects kidney Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Recombinant Proteins Renal Dialysis - adverse effects transferrin transferrin saturation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sensitivity to iron dextran is a potent obstacle to maintaining optimum iron status in patients with dialysis-associated anemia. As part of the North American clinical trials for iron sucrose injection, we examined the effect of intravenous (IV) iron sucrose in 23 hemodialysis patients with documented sensitivity to iron dextran, ongoing epoetin alfa therapy, and below-target-range hemoglobin (Hgb) levels (
ISSN:	0272-6386 1523-6838
DOI:	10.1053/ajkd.2000.8276